BOSTON--Incyte Pharmaceuticals of Palo Alto, Calif., and Oxford GlycoSciences of Oxford, UK, jointly launched the LifeProgram protein expression product last month at the IBC Drug Discovery Technology Conference here. LifeProgram facilitates the identification and validation of new drug targets, therapeutic proteins, and human disease markers. This new program provides an extensive proteomics database, software to analyze and visualize proteomics data, and access to optional customer-directed services at Oxford to develop custom protein expression data.
LifeProgram's dataset was generated from a variety of human tissues and cell cultures, selected to represent relevant therapeutic areas, such as cancer, the cardiovascular system, immunology, metabolic disease, and the central nervous system. Incyte and Oxford developed all of the data from hundreds of Oxford Pem protein expression maps, which are composed of two-dimensional gel electrophoresis images that display a range of proteins expressed in a tissue sample.